MosheTalpazMD

Oncology • Ann Arbor, MI

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Talpaz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Talpaz's full profile

Already have an account?

Office
1500 East Medical Center Dr
B1 Floor Cancer Ctr Recp B
Ann Arbor, MI 48109
Phone+1 734-936-9814

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1979 - 1980
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1971

Certifications & Licensure

MI State Medical License 2005 - 2027
TX State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Start of enrollment: 2008 Jun 19
Terminated
Phase 1, Phase 2
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 May 01
Completed
Phase 1, Phase 2
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Completed
Phase 1
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Start of enrollment: 2013 Sep 01
Withdrawn
Phase 1, Phase 2
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Start of enrollment: 2015 Jan 01
Unknown status
Phase 1
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Start of enrollment: 2018 Jan 26
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

803 citations
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson, Yi-Mi Wu, Pankaj Vats, Fengyun Su, Robert J. Lonigro
Nature Genetics. 2013-12-01
581 citations
Integrative clinical genomics of metastatic cancer
Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro, Pankaj Vats, Erin F. Cobain
Nature. 2017-08-02
53 citations
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
Francis J. Giles, Ronan T. Swords, Arnon Nagler, Andreas Hochhaus, Oliver G. Ottmann
Leukemia. 2013-01-01

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Leukemia Inhibitory Factor Functions in Parallel with Interleukin-6 to Promote Ovarian Cancer Growth
Karen McLean, Ronald J Buckanovich, Moshe Talpaz, Nature
The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid Leukemia
Dale L Bixby, Ivan P Maillard, Moshe Talpaz, Leukemia Research

Abstracts/Posters

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized...
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid LeukemiaJune 2018

Press Mentions

How Useful Is Next-Generation Sequencing for Patients with Advanced Cancer?March 12th, 2021
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH MeetingDecember 6th, 2020
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial ResultsAugust 13th, 2020
Join now to see all